Anti-E41LB/ EPB41L4B/ CG1 monoclonal antibody

Anti-E41LB/ EPB41L4B/ CG1 antibody for FACS & in-vivo assay

Target products collectionGo to EPB41L4B/EPB41L4B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2108-Ab-1/ GM-Tg-hg-MP2108-Ab-2Anti-Human EPB41L4B monoclonal antibodyHuman
GM-Tg-rg-MP2108-Ab-1/ GM-Tg-rg-MP2108-Ab-2Anti-Rat EPB41L4B monoclonal antibodyRat
GM-Tg-mg-MP2108-Ab-1/ GM-Tg-mg-MP2108-Ab-2Anti-Mouse EPB41L4B monoclonal antibodyMouse
GM-Tg-cynog-MP2108-Ab-1/ GM-Tg-cynog-MP2108-Ab-2Anti-Cynomolgus/ Rhesus macaque EPB41L4B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2108-Ab-1/ GM-Tg-felg-MP2108-Ab-2Anti-Feline EPB41L4B monoclonal antibodyFeline
GM-Tg-cang-MP2108-Ab-1/ GM-Tg-cang-MP2108-Ab-2Anti-Canine EPB41L4B monoclonal antibodyCanine
GM-Tg-bovg-MP2108-Ab-1/ GM-Tg-bovg-MP2108-Ab-2Anti-Bovine EPB41L4B monoclonal antibodyBovine
GM-Tg-equg-MP2108-Ab-1/ GM-Tg-equg-MP2108-Ab-2Anti-Equine EPB41L4B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2108-Ab-1/ GM-Tg-hg-MP2108-Ab-2; GM-Tg-rg-MP2108-Ab-1/ GM-Tg-rg-MP2108-Ab-2;
GM-Tg-mg-MP2108-Ab-1/ GM-Tg-mg-MP2108-Ab-2; GM-Tg-cynog-MP2108-Ab-1/ GM-Tg-cynog-MP2108-Ab-2;
GM-Tg-felg-MP2108-Ab-1/ GM-Tg-felg-MP2108-Ab-2; GM-Tg-cang-MP2108-Ab-1/ GM-Tg-cang-MP2108-Ab-2;
GM-Tg-bovg-MP2108-Ab-1/ GM-Tg-bovg-MP2108-Ab-2; GM-Tg-equg-MP2108-Ab-1/ GM-Tg-equg-MP2108-Ab-2
Products NameAnti-EPB41L4B monoclonal antibody
Formatmab
Target NameEPB41L4B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-EPB41L4B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species E41LB/ EPB41L4B/ CG1 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2108
    Target NameEPB41L4B
    Gene ID54566,54357,500464,713324,474797,101089905,519310,100059009
    Gene Symbol and Synonyms6430543G08Rik,CG1,D4Ertd346e,EHM2,Epb4.1l4b,EPB41L4B,LULU2,RGD1562988
    Uniprot AccessionQ9H329,B2RYE5
    Uniprot Entry NameE41LB_HUMAN,E41LB_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000095203
    Target ClassificationN/A

    The target: EPB41L4B, gene name: EPB41L4B, also named as CG1, EHM2. Predicted to be a structural constituent of cytoskeleton. Involved in several processes, including positive regulation of cell adhesion; positive regulation of keratinocyte migration; and wound healing. Acts upstream of or within actomyosin structure organization. Located in apical part of cell; cytosol; and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.